Figure 6
![Figure 6. CD19-CAR–modified TSCM mediate long-lasting antitumor responses. (A) In vivo bioluminescent imaging, (B) radiance, and (C) survival of NSG mice bearing systemic NALM6-GL leukemia xenografts after adoptive transfer of CD19-CAR–modified standard or TSCM-enriched CD8+ T cells (2.5 × 105) in conjunction with intraperitoneal injections of recombinant human IL-15 every other day (****P < .0001; log-rank [Mantel-Cox]; n = 5). Data shown are representative of 2 independent experiments. d, day.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/128/4/10.1182_blood-2015-11-683847/4/519f6.jpeg?Expires=1735818376&Signature=MgQw4yzzgl9w-AQ-2Q3AWFZNCNeNNGwHxT~9KnKA1JwKKTpQ5Zx2kmDdNTWrlivJMwf~-rkXk~86qroOEOuP9AsbnizoP~yoh1rccFfxGDTwY7Tnzd~csi06J-e7JmkPb7ETlE8vF-aKq5k~ftdyy9qjY2pF0jxfTyQWg2ebE~y4n2diS9OCzD7hBXgaEkLzrOrngi0u-rSVw4aaNsJ6qwlLmRoKOnC7EPEeQ8443hX~tPsEQUtrvKn-QeFSREllCYu7KbIogretcJiJQEwrNKT3pmq~e5l-tqTU6QNyKw93yLYxfMxX986clWGUh1~kB9Q4kP-ICkcyGIyNN3J1Uw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CD19-CAR–modified TSCM mediate long-lasting antitumor responses. (A) In vivo bioluminescent imaging, (B) radiance, and (C) survival of NSG mice bearing systemic NALM6-GL leukemia xenografts after adoptive transfer of CD19-CAR–modified standard or TSCM-enriched CD8+ T cells (2.5 × 105) in conjunction with intraperitoneal injections of recombinant human IL-15 every other day (****P < .0001; log-rank [Mantel-Cox]; n = 5). Data shown are representative of 2 independent experiments. d, day.
